Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid for Bone Loss Prevention in Osteopenia
NCT00132808Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2004
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zoledronic acid in osteopenia (3 arms), sponsored by Novartis. Primary endpoint: Percentage Change in Lumbar Spine Bone Mineral Density (BMD) at 24 months. Started Jul 2004; status: completed.
02
Drugs
zoledronic acid
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT00132808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132808.